Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma

References

• Howlade N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2009. Bethesda (MD): National Cancer Institute; 2012.
   Google Scholar
• Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25–35.
   PubMedGoogle Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403.
   PubMed Web of Science ®Google Scholar
• Anderson KC. The 39th David A. Karnofsky lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012;30:445–452.
   PubMed Web of Science ®Google Scholar
• FDA pomalidomide full prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdf
   Google Scholar
• EMA pomalidomide full prescribing information. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002682/WC500147717.pdf
   Google Scholar
• San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–1066.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Palumbo A, Corradini P, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128(4):497–503.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013;121(11):1961–1967.
   PubMed Web of Science ®Google Scholar
• Leleu X, Attal M, Amulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: intergroupe Francophone du Myélome 2009-02. Blood. 2013;121(11):1968–1975.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Zhang Q, Stratton K, et al. Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma. Leukemia. 2014;28(12):2413–2415.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826–1832.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Leleu X, Palumbo A, et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28:1573–1585.
   PubMed Web of Science ®Google Scholar
• Terpos E, Kleber M, Engelhardt M, et al. European Myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254–1266.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, et al.; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb;22(2):414–423.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Delforge M, Beksac M, et al. Management of treatment related peripheral neuropathy in multiple myeloma. Leukemia. 2012;26:595–608.
   PubMed Web of Science ®Google Scholar
• Geyer HL, Viggiano RW, Lacy MQ, et al. Acute lung toxicity related to pomalidomide. Chest. 2011;140:529–533.
   PubMed Web of Science ®Google Scholar
• Kortuem KM, Stewart AK. Carfilzomib. Blood. 2013;121:893–897.
   PubMed Web of Science ®Google Scholar
• Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753–1761.
   PubMed Web of Science ®Google Scholar
• Carfilzomib FDA full prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202714s009lbl.pdf
   Google Scholar
• Carfilzomib EMA full prescribing information. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003790/WC500197692.pdf
   Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38.
   PubMed Web of Science ®Google Scholar
• Siegel D. From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol. 2013;4(6):354–365.
   PubMedGoogle Scholar
• Danhof S, Schreder M, Rasche L, et al. “Real-life” experience of preapproval carfilzomib-based therapy in myeloma – analysis of cardiac toxicities and predisposing factors. Eur J Haematol. 2016;97(1):25–32.
   PubMed Web of Science ®Google Scholar
• Atrash S, Tullos A, Panozzo S, et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. 2015;5:e272. DOI:10.1038/bcj.2014.93
   PubMed Web of Science ®Google Scholar
• Rosenthal A, Luthi J, Belohlavek M, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016 Jan 15;6:e384. DOI:10.1038/bcj.2015.112
   Web of Science ®Google Scholar
• Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014;124:1047–1055.
   PubMed Web of Science ®Google Scholar
• Kumar SK, LaPlant B, Roy V, et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015 Aug 14;4:e338. DOI:10.1038/bcj.2015.60
   Web of Science ®Google Scholar
• Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014;15:1503–1512.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–1634.
   PubMed Web of Science ®Google Scholar
• Ixazomib FDA full prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf
   Google Scholar
• Richardson PG, Baz R, Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014;124:1038–1046.
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–440.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Grosicki S, Jedrzejczak W, et al. Randomized phase 2 study of the all-oral combination of investigational proteasome inhibitor (PI) ixazomib plus cyclophosphamide and low-dose dexamethasone (ICd) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) who are transplant-ineligible (NCT02046070). Blood. 2015;126:26.
   PubMed Web of Science ®Google Scholar
• Larocca A, Montefusco V, Bringhen S, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 2013;122:2799–2806.
   PubMed Web of Science ®Google Scholar
• Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126(20):2284–2290.
   PubMed Web of Science ®Google Scholar
• Jakuboviak AJ, Dytfeld D, Griffith KA, et al. A phase-I/II study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801–1809.
   PubMed Web of Science ®Google Scholar
• Korde N, Zingone A, Kwok ML, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients [abstract]. Blood. 2013;122(21):Abstract 538.
   Web of Science ®Google Scholar
• Jakuboviak AJ, Campioni M, Benedict A, et al. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ. 2016;19(11):1061–1074.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDS and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–157.
   PubMed Web of Science ®Google Scholar
• Elotuzumab FDA approval. Available from: http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm474719.htm
   Google Scholar
• Daratumumab FDA approval. Available from: http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm472904.htm
   Google Scholar
• Panobinostat FDA approval. Available from: http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm435339.htm
   Google Scholar
• Nooka AK, Kaufman JL, Lonial S. Efficacy and safety of triplet versus doublet salvage therapies among relapsed myeloma patients: meta-analysis of phase 3 randomized controlled trials. J Clin Oncol. 2016;34:abstr8020.
   Google Scholar
• Palumbo A, Chanan-Khan AA, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375:754–766.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumuab, lenalidomide, and dexamethasone for multiple myeloma. New Eng J Med. 2016;375:1319–1331.
   PubMed Web of Science ®Google Scholar
• Vij R, Lendvai N, Martin TG, et al. A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): interim results from two new dose cohorts. J Clin Oncol. 2016;34:abstr8009.
   Google Scholar
• Mateos MV, Orlowski RZ, Siegel DS, et al. Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): final efficacy and safety analysis. J Clin Oncol. 2016;34:abstr8010.
   Google Scholar
• Raab MS, Chatterjee M, Goldschmidt H, et al. MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: data from clinically relevant cohorts from a phase I/IIa study. J Clin Oncol. 2016;34:abstr8012.
   Google Scholar
• Laubach J, Tuchman SA, Rosenblatt J, et al. Phase 1b study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma. J Clin Oncol. 2016;34:abstr8014.
   Google Scholar
• San Miguel J, Raab MS, Goldschmidt H, et al. A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2016;34:abstrTPS8066.
   Google Scholar
• Shah JJ, Jagannath S, Mateos MV, et al. KEYNOTE-183: a randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma. J Clin Oncol. 2016;34:abstrTPS8070.
   Google Scholar
• Siegel DS, van de Donk N, Sonneveld P, et al. A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM). J Clin Oncol. 2016;34:abstrTPS8072.
   Google Scholar
• Shah J, Niesvizky R, Stadtmauer E, et al. Oprozomib, pomalidomide, and dexamethasone (OPomd) in patients (pts) with relapsed and/or refractory multiple myeloma (RRMM): initial results of a phase 1b study (NCT01999335). Blood. 2015;126:378.
   PubMed Web of Science ®Google Scholar
• Chari A, Lonial S, Suvannasankha A, et al. Open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma. Blood. 2015;126:508.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Offidani M, Pégourie B, et al. Elotuzumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: 2-year-follow-up. Blood. 2015;126:510.
   Web of Science ®Google Scholar
• Shah JJ, Feng L, Thomas SK, et al. Phase 1 study of the novel kinesin spindle protein inhibitor filanesib + carfilzomib in patients with relapsed and/or refractory multiple myeloma (RRMM). Blood. 2015;126:376.
   Web of Science ®Google Scholar
• Zonder JA, Usmani S, Scott EC, et al. Phase 2 study of carfilzomib (CFZ) with or without filanesib (FIL) in patients with advanced multiple myeloma (MM). Blood. 2015;126:728.
   Web of Science ®Google Scholar
• Palumbo A, Mateos MV, San Miguel J, et al. KEYNOTE-185: a randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM). J Clin Oncol. 2016;34:abstrTPS8069.
   Google Scholar
• Kumar SK, Berdeja JG, Niesvizky R, et al. 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9. San Francisco (CA). Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients (Pts) with previously untreated multiple myeloma (MM): phase 2 study results. Available from: https://ash.confex.com/ash/2014/webprogram/Paper69951.html
   Google Scholar
• Palumbo A, Morgan JG, Rajkumar SV, et al. Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and -MM4. J Clin Oncol. 2016;34:abstrTPS8068.
   Google Scholar
• Palumbo A, Gay F, Cavallo F, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33(30):3459–3466.
   PubMed Web of Science ®Google Scholar